AFM
NAUT icon

Anson Funds Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Anson Funds Management’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-449,516
Closed -$809K – 203
2022
Q4 		$809K Buy
+449,516
New +$868K 0.13% 121

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Anson Funds Management's NAUT Position: Q1 2023 in Review

Anson Funds Management sold out of Nautilus Biotechnolgy (NAUT) in Q1 2023, closing a stake of 449,516 shares — an estimated $809K sold.

Anson Funds Management first reported a position in NAUT in Q4 2022 and held it in 1 quarter. The position peaked at $809K in Q4 2022. 73 funds tracked by Wall St. Rank hold NAUT as of Q1 2023.

  • Anson Funds Management reported no remaining Nautilus Biotechnolgy position as of Q1 2023 after selling out during the quarter.
  • Anson Funds Management sold 449,516 Nautilus Biotechnolgy shares in Q1 2023, an estimated $809K.
  • Anson Funds Management first reported a position in Nautilus Biotechnolgy in Q4 2022 and held it in 1 quarter.
  • Anson Funds Management's Nautilus Biotechnolgy position peaked at $809K in Q4 2022.
  • 73 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q1 2023.

Based on Anson Funds Management's 13F filing for Q1 2023, filed 15 May 2023.